Literature DB >> 20403471

Effect of Angiotensin-converting enzyme inhibition on one-year mortality and frequency of repeat acute myocardial infarction in patients with acute myocardial infarction.

Christos Milonas1, Tomas Jernberg, Johan Lindbäck, Stefan Agewall, Lars Wallentin, Ulf Stenestrand.   

Abstract

Controversy exists regarding whether all patients with acute myocardial infarction (AMI) benefit from angiotensin-converting enzyme inhibitors (ACEIs). We examined the association between ACEI treatment and mortality in a large, unselected population of patients with AMI. The present study included 105,224 patients with AMI who were not treated with ACEIs on admission. A logistic regression analysis, including 33 variables, calculated a propensity score for each patient to estimate the probability of receiving ACEIs at discharge, given the background. The association between ACEI treatment at discharge and the 1-year outcome was evaluated in prespecified subgroups using the Cox regression analyses, adjusting for the propensity score and medications at discharge. A total of 38,395 patients (36.5%) received ACEIs at discharge. After adjustment, ACEI treatment was associated with a 24% reduction in mortality (relative risk 0.76, 95% confidence interval 0.73 to 0.80). The benefit was largest in patients with a history or present signs of heart failure. In patients without heart failure, a significant benefit of ACEI treatment was seen only in patients with renal dysfunction (relative risk 0.69, 95% confidence interval 0.54 to 0.88). In the whole group, the risk of AMI decreased by 7% (relative risk 0.93, 95% confidence interval 0.90 to 0.96), with a larger effect seen in patients with ST-segment elevation AMI or systolic left ventricular dysfunction. In conclusion, in unselected patients with AMI, ACEI treatment was associated with a reduction in 1-year mortality, mainly in patients with heart failure or renal dysfunction, and a small reduction in the risk of reinfarction, mainly in patients with ST-segment elevation AMI or systolic left ventricular dysfunction. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20403471     DOI: 10.1016/j.amjcard.2009.12.032

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  25 in total

1.  Cardiology: Bad matters made worse.

Authors:  Ira Tabas
Journal:  Nature       Date:  2012-07-18       Impact factor: 49.962

Review 2.  An emerging role for the miR-26 family in cardiovascular disease.

Authors:  Basak Icli; Pranav Dorbala; Mark W Feinberg
Journal:  Trends Cardiovasc Med       Date:  2014-06-12       Impact factor: 6.677

Review 3.  Cardiac macrophages and their role in ischaemic heart disease.

Authors:  Stefan Frantz; Matthias Nahrendorf
Journal:  Cardiovasc Res       Date:  2014-02-05       Impact factor: 10.787

4.  Myocardial Infarction Produces Sustained Proinflammatory Endothelial Activation in Remote Arteries.

Authors:  Federico Moccetti; Eran Brown; Aris Xie; William Packwood; Yue Qi; Zaverio Ruggeri; Weihui Shentu; Junmei Chen; Jose A López; Jonathan R Lindner
Journal:  J Am Coll Cardiol       Date:  2018-08-28       Impact factor: 24.094

5.  Long-term survival in patients with different combinations of evidence-based medications after incident acute myocardial infarction: results from the MONICA/KORA Myocardial Infarction Registry.

Authors:  Ute Amann; Inge Kirchberger; Margit Heier; Hildegard Golüke; Wolfgang von Scheidt; Bernhard Kuch; Annette Peters; Christa Meisinger
Journal:  Clin Res Cardiol       Date:  2014-03-07       Impact factor: 5.460

Review 6.  Monocyte heterogeneity in cardiovascular disease.

Authors:  Peter Libby; Matthias Nahrendorf; Filip K Swirski
Journal:  Semin Immunopathol       Date:  2013-07-10       Impact factor: 9.623

Review 7.  Monocyte and macrophage heterogeneity in the heart.

Authors:  Matthias Nahrendorf; Filip K Swirski
Journal:  Circ Res       Date:  2013-06-07       Impact factor: 17.367

8.  Bifurcation and dynamics in a mathematical model of early atherosclerosis: How acute inflammation drives lesion development.

Authors:  Alexander D Chalmers; Anna Cohen; Christina A Bursill; Mary R Myerscough
Journal:  J Math Biol       Date:  2015-03-03       Impact factor: 2.259

9.  Prognostic impact of early ventricular fibrillation in patients with ST-elevation myocardial infarction treated with primary PCI.

Authors:  Marina M Demidova; J Gustav Smith; Carl-Johan Höijer; Fredrik Holmqvist; David Erlinge; Pyotr G Platonov
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2012-12

Review 10.  Imaging and nanomedicine in inflammatory atherosclerosis.

Authors:  Willem J M Mulder; Farouc A Jaffer; Zahi A Fayad; Matthias Nahrendorf
Journal:  Sci Transl Med       Date:  2014-06-04       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.